PART I Overview We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary ...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001493152-26-013612 | EDGAR | 101K words |
| 2025-03-27 | 2024-12-31 | 0001641172-25-000926 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0001493152-24-010302 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0001493152-23-008241 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001213900-22-011581 | EDGAR | — |
| 2021-03-10 | 2020-12-31 | 0001213900-21-014576 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001493152-25-021927 | EDGAR | 20K words |
| 2025-08-13 | 2025-06-30 | 0001641172-25-023471 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010547 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001493152-24-044010 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001493152-24-030766 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001493152-24-018422 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001493152-23-039896 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001493152-23-027345 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001493152-23-015940 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001493152-22-030819 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001493152-22-021610 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0001213900-22-023583 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-03 | 0001493152-26-035864 | EDGAR | — |
| 2026-03-30 | 0001493152-26-013608 | EDGAR | 5K words |
| 2026-01-23 | 0001493152-26-003314 | EDGAR | — |
| 2025-11-13 | 0001493152-25-022134 | EDGAR | — |
| 2025-09-23 | 0001493152-25-014652 | EDGAR | — |
| 2025-08-13 | 0001641172-25-023489 | EDGAR | — |
| 2025-07-29 | 0001641172-25-021407 | EDGAR | — |
| 2025-07-03 | 0001641172-25-017810 | EDGAR | — |
| 2025-05-15 | 0001641172-25-010541 | EDGAR | — |
| 2025-03-27 | 0001641172-25-000917 | EDGAR | — |
86 total filings indexed. 58 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001763950 |
| Ticker | LTRN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | TX |
| Website | https://www.lanternpharma.com |
| Listed | 2020-06-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LTRN (~200 tokens, structured JSON with cryptographic provenance)